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KMT2A promotes melanoma cell growth by targeting
hTERT signaling pathway
Changlin Zhang1,5, Chen Song2,5, Tianze Liu1,5, Ranran Tang2, Miao Chen1, Fan Gao1, Binyi Xiao1, Ge Qin1, Fen Shi3,
Wenbin Li1, Yixin Li1, Xiaoyan Fu1, Dingbo Shi1, Xiangsheng Xiao1, Lan Kang2, Wenlin Huang1,4, Xiaojun Wu*,1, Bing Tang*,3 and
Wuguo Deng*,1,4
Melanoma is an aggressive cutaneous malignancy, illuminating the exact mechanisms and finding novel therapeutic targets are
urgently needed. In this study, we identified KMT2A as a potential target, which promoted the growth of human melanoma cells.
KMT2A knockdown significantly inhibited cell viability and cell migration and induced apoptosis, whereas KMT2A overexpression
effectively promoted cell proliferation in various melanoma cell lines. Further study showed that KMT2A regulated melanoma cell
growth by targeting the hTERT-dependent signal pathway. Knockdown of KMT2A markedly inhibited the promoter activity and
expression of hTERT, and hTERToverexpression rescued the viability inhibition caused by KMT2A knockdown. Moreover, KMT2A
knockdown suppressed tumorsphere formation and the expression of cancer stem cell markers, which was also reversed by
hTERToverexpression. In addition, the results from a xenograft mouse model confirmed that KMT2A promoted melanoma growth
via hTERT signaling. Finally, analyses of clinical samples demonstrated that the expression of KMT2A and hTERTwere positively
correlated in melanoma tumor tissues, and KMT2A high expression predicted poor prognosis in melanoma patients. Collectively,
our results indicate that KMT2A promotes melanoma growth by activating the hTERT signaling, suggesting that the KMT2A/hTERT
signaling pathway may be a potential therapeutic target for melanoma.
Cell Death and Disease (2017) 8, e2940; doi:10.1038/cddis.2017.285; published online 20 July 2017
Melanoma is one of the most deadly cutaneous malignancies
and increases in occurrence in the past several decades.1–4
Currently, there may be one million melanoma patients in the
United States. Up to 20% of the patients will develop
metastatic tumors eventually, and the 5-year survival rate of
them is o5% after the occurrence of metastasis.5 In recent
years, improved knowledge of the pathophysiology of mela-
noma and a better understanding of the role of the immune
system in tumor control have led to the development and
application of several immunotherapies.6 Monoclonal anti-
bodies against different immune checkpoints have revolutio-
nized the treatment of metastatic and unrespectable
melanoma. Ipilimumab and pembrolizumab have been shown
to target cytotoxic T-lymphocyte antigen 47 and programmed
cell death protein 1,8 respectively, whereas vemurafenib
targets BRAF signaling pathway.9 These therapies have
prolonged the overall survival (OS) in patients with advanced
melanoma. However, fair proportions of melanomas are BRAF
wild type, NRAS-mutant or TERT-mutant, and hence are
insensitive to these vemurafenib.10,11 Also, metastatic mela-
nomas still need good treatment options, as the underlying
mechanisms ofmelanoma progression andmetastasis are not
well acknowledged.12 Therefore, it is crucial to discover and
identify potential key players in melanoma tumorigenesis for
the development of novel cancer therapeutics.
Lysine methyltransferase 2A (KMT2A), also known as
mixed-lineage leukemia (MLL) or acute lymphoblastic leuke-
mia 1 (ALL-1), is a transcriptional co-activator regulating gene
expression during early development and hematopoiesis.13,14
The KMT2A protein contains multiple conserved functional
domains,15 and the SET domain is responsible for its histone
H3 lysine 4 (H3K4) methyltransferase activity that mediates
chromatin modifications associated with epigenetic trans-
criptional activation.16,17 KMT2A is processed by taspase 1
into two fragments, MLL-C and MLL-N. These fragments
re-associate and further assemble into different multiprotein
complexes that regulate the transcription of specific target
genes.18–20 It has been shown that aberrant chromosomal
rearrangements of KMT2A generated the MLL-AF9 fusion
protein that initiated murine acute myeloid leukemia.21 Other
reports have shown that MLL fusion oncoprotein drive the
expression of homeobox genes such as HOXA cluster genes
and myeloid ecotropic viral integration site 1, which are known
to induce leukemic transformation of hematopoietic
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progenitors and predict poor diagnosis for the disease.22
Furthermore, the expression of KMT2A is usually essential for
the senescence-associated secretory phenotype,23 and
KMT2A has been found to interact with the NF-κB pathway
to regulate brain cancer growth.24 In addition, new findings
have demonstrated that KMT2A negatively regulates cell
migration and invasion in cervical cancer.25,26 However, the
role of KMT2A in cancers other than MLL remains largely
unknown.
Telomeres are repetitive (TTAGGG)n DNA elements at the
ends of chromosomes and shorten with each cell division,
eventually leading to senescence (aging).27,28 Telomerase
adds the six-nucleotide repeating sequence onto the ends of
chromosomes, providing a telomere maintenance mechanism
for over 80% of human cancers. Human telomerase reverse
transcriptase (hTERT) is the catalytic protein component of
telomerase29 and expressed only in specific germ line cells,
proliferative stem cells of renewal tissues, and cancer
cells.30,31 Overexpression of hTERT is a common feature
of most human cancers believed to support cell immortali-
zation.32–34 So far, it is known that hTERT is modulated at
genetic, mRNA, protein and subcellular localization levels,31
and transcription factors including c-Myc, NF-κB, STAT
proteins and estrogen receptors35 have been reported to bind
to the hTERT promoter to modulate its expression. The highly
recurrent mutations in the promoter of TERTare found in over
50 cancer types, including papillary thyroid carcinoma,36,37
hepatocellular carcinoma,38 epithelioid glioblastoma,39
bladder cancer,40 malignant pleural mesothelioma,41 mela-
noma,42–45 are the most common mutation in many cancers.
The newly described gremlin and recurrent somatic mutations
in melanoma and other cancers in the TERT promoter, which
create de novoE-twenty six/ternary complex factors (Ets/TCF)
binding sites,44,45 provide an insight into the possible cause
of tumor-specific increased TERT expression. However, the
precise mechanism behind the TERT activation in cancers
remained unknown.
In our siRNA library screening, we identified a series of new
proteins implicated in melanoma growth and progression.
Among them, we chose KMT2A to evaluate its function in
melanoma cell growth and apoptosis. Moreover, we explored
the potential molecular mechanisms by which KMT2A
regulated cell growth and its clinical significance. Our results
showed that knockdown of KMT2A inhibited cell proliferation
and induced apoptosis by activating the caspase-dependent
signaling pathway, KMT2A promoted cell growth via hTERT
signaling, and high expression of KMT2Awas associated with
poor prognosis in melanoma patients. Our study has not only
revealed the role of KMT2A in melanoma progression for the
first time, but also identified a potential therapeutic target for
melanoma treatment.
Results
KMT2A knockdown inhibited cell proliferation in mela-
noma cells. To discover and identify potential molecules and
signaling pathways involved in the growth of melanoma, we
screened a siRNA library targeting 46000 human genes in
A375 melanoma cells and found that KMT2A knockdown by
siRNA significantly suppressed the cell viability by 76.0%
(Figure 1a), indicating that KMT2A, a transcriptional
co-activator in cancer,15,46,47 could be a melanoma target.
To assess the role of KMT2A in melanoma cells, we first
determined the expression levels of KMT2A in a panel of
human melanoma cell lines (A375, MeWo, A431, WM35). The
expression of KMT2A protein was detected by western blot,
and the relative density were also analyzed (Figure 1b and c
and Supplementary Fig. 1A, 1B). The results showed that
knockdown of KMT2A by its specific shRNAs inhibited the
expression of KMT2A (Figure 1b and Supplementary Fig. 1A),
whereas overexpression of KMT2A markedly increased the
expression of KMT2A (Figure 1c and Supplementary Fig. 1B).
To validate that KMT2A could promote melanoma cell
proliferation; we measured its effect on the viability of
human melanoma cell lines (A375, MeWo, A431, WM35) by
MTS assay. Knockdown of KMT2A by its specific shRNAs
significantly inhibited the viability of all the tested cell lines
(Figure 1d and Supplementary Fig. 1C). In contrast, over-
expression of KMT2A markedly increased the viability of
the cells (Figure 1e and Supplementary Fig. 1D). Collectively,
these results confirmed that KMT2A promoted melanoma
cell growth.
KMT2A Knockdown suppressed migration and induced
apoptosis in melanoma cells. Next, we evaluated the
effect of KMT2A knockdown on cell migration in A375 and
MeWo cells by wound-healing assay. After 48 h, a scratch
was made, the width of the gap or wounding space between
cell layers remained distinct in cells treated with KMT2A-
specific shRNAs, but the gap was almost fully occupied
by the migrating cells in the control group (Figure 1f and g).
We further determined whether the inhibition of cell
migration caused by KMT2A knockdown was associated with
apoptosis. A375 and MeWo cells transfected with KMT2A-
specific or scrabled control shRNAs for 48 h were harvested
and subjected to apoptosis analysis by FACS. We found that
a higher percentage of cells with KMT2A knockdown were
apoptotic compared with the control (Figure 1h and i).
To illuminate the underlying molecular mechanism by which
KMT2A knockdown inhibited cell migration and promoted
apoptosis in melanoma, we analyzed the expression of a
series of migration-related proteins and apoptosis-related
proteins possibly affected by KMT2A. As shown in Figure 1j
and k, KMT2A knockdown in A375 cells markedly decreased
the expression of the migration markers MMP2 and MMP9,
but increased the expression of cleaved-caspase3, cleaved-
caspase7, cleaved-caspase9 and cleaved-PARP proteins.
These results together indicated that knockdown of KMT2A in
melanoma suppressed cell migration and induced apoptosis,
which was at least partially mediated via the activation of
the caspase-dependent signaling pathway.
KMT2A bound to the promoter of hTERT to regulate its
expression. Considering that KMT2A has been reported to
regulate the expression of its target genes at their promoter
regions, we examined whether it directly modulated the
expression of genes involved in melanoma growth. hTERT
opposes cellular senescence and is highly expressed in
490% of human cancers48 with a key role in melanoma
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Figure 1 KMT2A was identified as a potential melanoma target. (a) A brief summary of the siRNA library screening results. (b and c) The KMT2A expression level was detected by
western blot and the relative optical density % were analyzed in melanoma A375 and MeWo cells with KMT2A knockdown (b) or overexpression (c). (d and e) Viability of A375 and MeWo
cells with KMT2A knockdown (d) or overexpression (e) wasmeasured byMTS assay. (f) Migration ability of A375 andMeWo cellswith KMT2A knockdown wasmeasured by wound-healing
assay and the average gap width (μm) (g). (e) Apoptosis of A375 and MeWo cells with KMT2A knockdown was detected by FACS analysis and the relative apoptosis of cell % (i).
(j and k) The expression of KMT2A, MMP2, MMP9 and the cleaved caspase3, caspase7, caspase9 and PARP proteinswere detected by western blot in A375 cells with KMT2A knockdown
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progression.49 Therefore, we hypothesized that KMT2A
promoted melanoma growth through regulating hTERT
expression.
We first assessed the regulation of hTERT protein and
mRNA expression by KMT2A in melanoma cells by western
blot and qRT-PCR analysis. As shown in Figure 2a and c, the
protein and mRNA levels of hTERT were reduced when
KMT2A was silenced, but were significantly increased
when KMT2A was overexpressed (Figure 2b and d), support-
ing that KMT2A could regulate melanoma growth via hTERT
signaling.
The regulation of hTERTexpression occurs throughmultiple
avenues including CpG promoter methylation,50 alternative
splicing51 and so on, and transcriptional regulation is the
limiting step.52 A number of factors have been identified to
regulate the activity of the hTERT promoter directly or
indirectly.53,54,55 To test if KMT2A anchored at the hTERT
promoter to regulate its expression, ChIP assay was
performed in melanoma cells. The results showed that the
hTERT promoter region was amplified by PCR from the
complexes immunoprecipitated by the antibody against
KMT2A, but not from the complexes precipitated by the IgG
negative control (Figure 2e and f).
Mutations in the TERT promoter have been found in
melanoma44,45 and are known to regulate TERT expression.
To determine whether KMT2A bind to the segment of hTERT
promoter associated with mutations, ChIP-qPCR assay was
performed. The smaller hTERT promoter fragments were
amplified by PCR. As shown in Figure 2g, the fragments
−234~−144 and −871~−696 were more enrich than the
other fragments, especially the − 871~−696 fragment, indi-
cating that these regions maybe the regions that KMT2A
bound on the promoter of hTERT.
Next, we investigated the effect of KMT2A on the
hTERT promoter activity. The luciferase reporter assay
showed that knockdown of KMT2A significantly decreased
the hTERT promoter activity in A375 cells compared with
the non-silencing shRNA control (Figure 2k), whereas over-
expression of KMT2A markedly enhanced the hTERT
promoter activity (Figure 2l). Taken together, these data
indicated that KMT2A promoted hTERT expression at the
transcriptional level through binding to its promoter in
melanoma cells.
We also investigated the effect of KMT2A on telomerase
activity and telomerase length. The ELISA assay showed that
knockdown of KMT2A significantly decreased the telomerase
activity in A375 and MeWo cells (Figure 2h), whereas
overexpression of KMT2Amarkedly enhanced the telomerase
activity (Figure 2i). The Telo TAGGG Telomere Length Assay
showed that knockdown of KMT2A significantly decreased the
telomerase length in A375 cells compared with the non-
silencing shRNA control (Figure 2j), whereas overexpression
of KMT2A markedly enhanced the telomerase length
(Figure 2j). These data indicated that KMT2A regulated
telomerase activity and telomerase length through binding to
hTERT promoter in melanoma cells.
In addition, to determine whether knockdown of KMT2A
inhibited melanoma cell growth through regulating hTERT
expression, MTS assay was performed to explore if over-
expression of hTERT could offset the inhibitory effect caused
by KMT2A knockdown. As shown in Figure 2m and n, cell
viability was inhibited when KMT2A was silenced, but this
inhibition was partly rescued by hTERT overexpression in
A375 cells, confirming that KMT2A controlled cell growth
through hTERT.
KMT2A regulated cancer stem cell marker expression
and tumorsphere formation through hTERT signaling.
Accumulating evidence suggests that hTERT is associated
with the characteristics of caner stem cells.56–58 Given that
hTERT had a role in tumorsphere formation, we examined if
KMT2A could promote the stemness of melanoma cells
through the hTERT signaling pathway. The tumorsphere
formation assay in A375 cells showed that knockdown of
KMT2A markedly decreased the expression of the stem cell
markers Nanog, oct-4 and sox-2, and significantly repressed
the tumorsphere formation ability of cells (Figure 3a). In
contrast, overexpression of KMT2A increased the expression
of Nanog, oct-4 and sox-2, and enhanced the tumorsphere
formation ability of cells (Figure 3b). Moreover, overexpres-
sion of hTERT partially reversed the tumorsphere formation
inhibition caused by KMT2A knockdown (Figure 3c and d),
suggesting that KMT2A regulated the expression of cancer
stem cell markers and tumorsphere formation in melanoma
via the hTERT signaling pathway.
KMT2A knockdown inhibited melanoma progression in a
mouse xenograft model. The oncogenic role of KMT2A in
melanoma was further examined in a mouse xenograft
model. A375 cells (5 × 106 in 100 μl PBS) were injected
subcutaneously into the left flank of female athymic nude
mice aged 3–4 weeks. When the formed tumor reached
100 mm3, the animals were randomly divided into five groups
(five per group) and, respectively, intratumorally injected with
the control shRNA, KMT2A shRNA, KMT2A shRNA+hTERT
overexpression, vector and KMT2A overexpression once
every three days for six times. After administration for
18 days, both the tumor volumes (Figure 4c and e) and
Figure 2 KMT2A bound to the promoter of hTERT to regulate its expression. (a and b) The protein levels of KMT2A and hTERT in A375 and MeWo cells with KMT2A
knockdown (a) or overexpression (b) were analyzed by western blot. β-actin served as the loading control. (c and d) The mRNA expression of KMT2A and hTERT in A375 and
MeWo cells with KMT2A knockdown (c) or overexpression (d) were detected by qRT-PCR. (e) ChIP was performed to detect the binding of KMT2A at the hTERT promoter.
(f) Quantification of (e). P-con means the GAPDH primers, a positive control to demonstrate the efficacy of the EpiQuikTM Chromatin Immunoprecipitation Kit reagents and
protocol. (g) ChIP-qPCR was performed to detect the binding of KMT2A at smaller fragments of hTERT promoter. (h and i) Telomerase activity in A375 and MeWo cells with
KMT2A knockdown (h) or overexpression (i) was analyzed by Telo TAGGG Telomerase PCR ELISA assay kit. (j) The telomerase length in A375 cells with KMT2A knockdown and
overexpression was analyzed by Telo TAGGG Telomerase length assay kit. (k and l) The activity of the hTERT promoter in A375 cells with KMT2A knockdown (K) or
overexpression (l) was measured by dual-luciferase assay. (m) hTERT expression was detected by western blot in A375 cells with KMT2A knockdown alone or together with
hTERT overexpression. (n) MTS assay was performed to measure the viability of the cells in (m)
KMT2A promotes melanoma cell growth
C Zhang et al
4
Cell Death and Disease
tumor weight (Figure 4d and f) were measured. As shown in
Figure 4a-e, knockdown of KMT2A markedly suppressed
melanoma tumor growth in size, volume and weight, whereas
overexpression of KMT2A promoted tumor growth. Further-
more, hTERToverexpression remarkably reversed the growth
inhibition caused by KMT2A knockdown. In addition, all these
KMT2A promotes melanoma cell growth
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treatments did not significantly affect the body weight of the
mice (Figure 4f), and no other signs of acute or delayed
toxicity were observed in the mice during treatment.
Furthermore, the results from western blot analysis
of tissue lysates of the xenograft tumors demonstrated that
co-treatment with KMT2A-shRNA1 and hTERT plasmid in
the mice enhanced the expression of hTERT, which was
suppressed when treatment with KMT2A-shRNA1
(Figure 4g). The HE staining also showed that the tumor cells
in the nonspecifically shRNA-treated control mice were
irregular and had abundant cytoplasm, and large and
deformity nuclei (data were not shown). Moreover, the
expression of KMT2A and hTERT was determined by
immunohistochemical (IHC) staining. Consistent with the
in vitro results (Figure 2a and g), knockdown of KMT2A
significantly decreased the levels of KMT2A and hTERT. All
these results from the xenograft model indicated that KMT2A
knockdown indeed had anti-cancer effects in melanoma,
which were at least partially achieved by activating the hTERT
signal pathway.
Expression of KMT2A and hTERT was positively corre-
lated in melanoma patient samples. To uncover the clinical
significance of KMT2A and further confirm its relevance with
hTERT, we detected their expression in melanoma tissue
samples. The level of KMT2A expression was categorized
into three classes (high, moderate and low), and the
representative staining images of KMT2A and hTERT in
melanoma and normal tissues were shown in Figure 5a.
Among the 48 samples tested (Supplementary Table 1), 6
(12.5%) had high KMT2A expression and 22 (45.8%) had low
KMT2A expression, whereas 40 (83.3%) had high hTERT
expression and 5 (10.4%) had low hTERT expression
(Figure 5b). Correlation analysis showed that the expression
of KMT2A and hTERT were positively correlated in human
melanoma (P=0.0444) (Figure 5c). Also, the relationships
between hTERT expression and different clinicopathologic
variables were analyzed (Figure 5d-i), and the expression of
hTERT was significantly correlated with the location
(P= 0.0292) (Figure 5f) and the metastatic status of the
melanoma tissues (P= 0.0298) (Figure 5h).
Figure 3 KMT2A regulated cancer stem cell marker expression and tumorsphere formation through hTERT signaling. (a and b) Human melanoma A375 cells were
transfected with KMT2A shRNAs or KMT2A overexpression plasmid. After 48 h of transfection, the levels of Nanog, oct-4 and sox-2 were analyzed by western blot. β-actin served
as the loading control. Also, the tumorsphere formation ability was tested, and representative images were displayed. (c) hTERT, Nanog, oct-4 and sox-2 expression was detected
by western blot in A375 cells with KMT2A knockdown alone or with KMT2A knockdown and hTERToverexpression. (d) The tumorsphere formation ability in the cells in (c) was
examined. Cells with representative morphology were shown. For quantification, more than 100 cells were inspected per experiment
KMT2A promotes melanoma cell growth
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High expression of KMT2A predicted poor prognosis in
melanoma patients. Analysis of the relationships between
KMT2A expression and different clinicopathologic variables
(Figure 6a-f) showed that the expression of KMT2A was
significantly correlated with the location (P= 0.0156)
(Figure 6c) and the growth pattern of melanoma
(P= 0.0253 and 0.0064) (Figure 6f). We further investigated
the prognostic role of KMT2A in melanoma patients. The OS
analysis indicated that the patients with KMT2A low expres-
sion had a significantly higher survival rate compared with
those with KMT2A high expression (Figure 6g), which was
supported by the hazardous coefficient analysis (Figure 6h).
Collectively, our clinical results validated the protumorigenic
function of KMT2A in melanoma, and suggested that it was
mediated through the hTERT signaling pathway.
Discussion
In the past 20 year, much progress has been made in
understanding the structure and biological functions of the
KMT2A protein.15,59 However, very few studies have explored
the functions of KMT2A in malignant melanoma. In this study,
we have demonstrated the functional significance of KMT2A in
melanoma progression in vitro and in vivo. KMT2A was
identified as a candidate target from a siRNA library screening,
and we found that KMT2A knockdown inhibited cell prolifera-
tion, promoted apoptosis and suppressed the growth of
melanoma xenograft. Our further analysis showed that
KMT2A knockdown suppressed the expression of MMP2,
MMP9 and promoted the cleavage of Caspase3/Caspase7/
Caspase9 and PARP in melanoma cells, and repressed the
expression of hTERT and the Nanog/oct-4/sox-2 stem cell
markers. Importantly, we uncovered that KMT2A bound at the
promoter of hTERT to regulate its expression (Supplementary
Fig. 2). Overexpression of hTERT partially reversed the
inhibitory effects caused by KMT2A knockdown on melanoma
growth and tumorsphere formation, suggesting that KMT2A
promoted melanoma growth in part via the hTERT pathway. In
addition, our clinical data indicated that KMT2A and hTERT
were positively correlated and KMT2A high expression
predicted poor prognosis in melanoma patients. To the best
of our knowledge, it is the first study to document the role and
Figure 4 KMT2A knockdown inhibited melanoma progression in a mouse xenograft model. Control shRNA (Con), KMT2A-shRNA (SH1), KMT2A-shRNA+hTERT
overexpression (SH1+hTERT), empty vector (Vector) and KMT2A overexpression plasmid (KMT2A) were intratumorally injected into mice. (a) Representative photographs of the
tumor bearing mice. (b) Morphology of tumor xenograft from each mouse. (c) Tumor volume of each mouse at the time of sacrifice. (d) Tumor weight of each mouse at the end of
the experiment. (e) Tumor volume of each mouse was measured and recorded every three days through the course of the experiment. (f) Body weight of each mouse was
monitored. (g) The expression of KMT2A and hTERT in tumor xenografts were tested by western blot
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molecular mechanism of KMT2A inmelanoma carcinogenesis
and development.
hTERTencodes a rate-limiting catalytic subunit of telomer-
ase that maintains genomic integrity.60 In our study, ChIP
assay showed that KMT2A bound to the promoter of hTERT
(−1655~+40) in melanoma cell lines. Recurrent and mutually
exclusive C4Tor CC4TT transition mutations were identified
in the promoter region of the reverse transcriptase catalytic
subunit of the telomerase gene (TERT) in melanoma,
suggesting that they enhanced the expression of TERT gene
and played important roles in the melanoma pathogenesis.42
We also determined whether KMT2A bind to the segment of
hTERT promoter associated with mutations. The results from
ChIP-qPCR showed that the fragments −234~−144 and
–871~−696 were more enrichment than the other fragments,
especially the −871 ~− 696 fragment. These results were not
the same as the previous studies. The most recurrent
melanoma nucleotide substitution has been shown to include
BRAF (chr7, 140,453,136A4T V600E), NRAS (chr1, 115,
256, 529T4C Q61R) and TERT core promoter mutations
(C228Tand C250T),44 but the precise mechanism behind the
TERTactivation in cancers remains largely unknown and need
to be studied in the future.
Telomerase has a pivotal role in cancer by maintaining
the ends of chromosomes and the potential for unlimited
proliferation in cells.48 As the catalytic subunit of telomerase,
hTERT determines the activity of telomerase.61 Multiple
transcription factor binding sites exist in the promoter region
of hTERT, and its expression is tightly controlled by transcrip-
tional activactors62,63 and tumor suppressors.35 Besides,
methylation of the histones at the hTERT promoter region
recruits histone acetyl transferase and promotes hTERT
transcription.64 Nonetheless, it remains unclear how hTERT
is regulated in melanoma.
KMT2A is a transcriptional co-activator with H3K4 methyl-
transferase activity.16 Its genetic rearrangements often result
Figure 5 KMT2A expression was positively correlated with hTERTexpression in melanoma patient tissues. (a) Representative images of the immunohistochemical staining
of KMT2A and hTERT in human normal and melanoma tissues. 200 × and 400 × magnification. (b and c) The correlation between the expression of KMT2A and hTERT in
human melanoma tissues from 48 patients. (d–i) Correlation analyses of hTERT protein expression in relation to different clinicopathologic variables in melanoma patient tissues
KMT2A promotes melanoma cell growth
C Zhang et al
8
Cell Death and Disease
in ontogenetic fusion proteins causing acute leukemia in
pediatric and adult patients.65–67 Here, we discovered that
KMT2A regulated the expression of hTERT by binding to its
promoter. Further investigation is needed to determine
whether KMT2A activates hTERT by methylating the histones
at its promoter, and whether the activation of hTERT is caused
by a novel mechanism other than the chromosomal trans-
locations of KMT2A.
In summary, our study has revealed a potential oncogenic
role of KMT2A in melanoma. Our results demonstrated that
KMT2A bound at the promoter of hTERT to activate its
expression, and thus promoted melanoma growth through the
hTERT pathway in cell lines and a xenograft mouse model.
Furthermore, high expression of KMT2A was related to
poor prognosis in melanoma patients, suggesting that
KMT2A could be a potential biomarker for the diagnosis and
a therapeutic target for the treatment of melanoma in the
future.
Materials and Methods
Cell lines and cell culture. Human melanoma cell lines A375, MeWo, A431
and WM35 were from ATCC, cultured in DMEM with 10% FBS, 100 μg/ml penicillin
and 100 μg/ml streptomycin, and maintained in standard culture condition.
Reagents and antibodies. GAPDH and β-actin antibodies were from
Proteintech (Rosemont, IL, USA). KMT2A, MMP2, MMP9, cleaved-caspase3,
cleaved-caspase7, cleaved-caspase9, cleaved-PARP, Nanog, oct-4 and sox-2
antibodies were from Cell Signaling Technology (Beverly, MA, USA). hTERT
antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Novus
NB110-89471.
Plasmid vectors. The plasmid pMSCV-FlagMLL-pl-ENL (5613) (KMT2A) and
its corresponding vector were gifts from Robert Slany (Addgene plasmid # 20873).
Recombinant plasmid pGL3-hTERT-438 expressing luciferase driven by an hTERT
promoter (−1655 to +40) was constructed in our laboratory.
Figure 6 High expression of KMT2A predicted poor prognosis in melanoma patients. (a–f) Correlation analyses of KMT2A protein expression in relation to different
clinicopathologic variables in 48 melanoma tissue samples. (g) Kaplan–Meier analysis showed high overall survival of melanoma patients with low KMT2A expression. (h) Hazard
analysis showed high KMT2A expression predicted low overall survival of melanoma patients
KMT2A promotes melanoma cell growth
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shRNA design. The shRNAs (see Supplementary Table 2 for sequences) were
purchased from Shanghai GenePharma Company (Shanghai, China).
Cell viability assay. Cell viability was determined using the MTS assay
(Roche Diagnosis, Indianapolis, IN, USA).
Wound-healing assay. Wound-healing assay was used to detect cell
migration ability and performed as described in ref. 68.
Apoptosis assay. Apoptosis assay was performed as described in ref. 69.
Nuclear extraction. Nuclear extraction was done as described in ref. 70.
Chromatin immunoprecipitation (ChIP) assay. ChIP experiment was
performed using EpiQuikTM Chromatin Immunoprecipitation Kit (Bsae Catalog #
P-2002) according to the manufacturer’s instructions, and the primers for PCR
amplification of the hTERT promoter are in Supplementary Table 2.
Telomerase activity assay. Telomerase activity was analyzed by Telo
TAGGG Telomerase PCR enzyme-linked immunosorbent assay kit (Roche, REF
11854666910) according to the manufacturer’s instructions.
Telomerase length assay. Telomere length was measured by a highly
sensitive nonradioactive chemiluminescence assay utilizing southern blot analysis of
terminal restriction fragments obtained by digestion of genomic DNA with frequently
cutting restriction enzymes (HinfI/RsaI) with a Telo TAGGG telomere length assay kit
(Roche, REF 12209136001) according to the manufacturer’s instructions. Telomeric
smears were revealed by exposure on X-ray film.
Promoter reporters and dual-luciferase assay. The core promoter
region of hTERT (−1655 to +40) was inserted between the SacI and HindІІІ sites
of the firefly luciferase vector pGL4.10 (Promega, Madison, WI, USA), and Renilla
luciferase reporter vector pRL-TK was used as a control. Dual-luciferase assay was
performed as described in ref. 68 and the luciferase activity was measured using
the Dual-Luciferase Reporter Assay System (Promega).
Western blot. Western blot was performed as described in ref. 68.
Real time PCR (qPCR). SYBR Green PCR master mix (Toyobo Life Science,
Shanghai, China) was used for qPCR, followed by detection with a Bio-Rad CFX96
and analyzed with the Bio-Rad Manager software (Bio-Rad, Hercules, CA, USA). The
PCR primers were synthesized by TaKaRa and were purchased from GeneCopoeia
(KMT2A Hs-QRP-33581, TERT Hs-QRP-22639, GAPDH Hs-QRP-20169) (see
Supplementary Table 2 for sequences).
Animal experiment and tissue processing. All animal procedures were
performed in accordance with the Guide for the Care and Use of Laboratory
Animals (NIH publications Nos. 80-23, revised 1996) and the Institutional Ethical
Guidelines for Animal Experiments developed by Sun Yat-sen University. A375 cells
(5 × 106 in 100 μl PBS) were injected subcutaneously into the left flank of female
athymic nude mice aged 3–4 weeks. When the formed tumor reached 100 mm3, the
animals were randomly divided into five groups (five per group) and, respectively,
intratumorally injected with control shRNA, KMT2A shRNA, KMT2A shRNA+hTERT
overexpression, vector and KMT2A overexpression once every three days for six
times. The tumor size was measured using a Vernier caliper and the tumor volume
was calculated as V= (length × width × height)/2. The experiment was terminated
22 days after tumor cell inoculation. The mice were then killed and the tumors were
excised and weighed.
Tumor tissues from the above treated animals were processed as described
in ref. 68.
Melanoma tissue microarray and IHC assay. Tissue microarray for
KMT2A and hTERTexpression was purchased from Fanpu Biotech, Inc. (Guilin, China),
with 48 melanoma tissues from patients without anti-cancer treatments. Clinicopatho-
logic information was documented for all cases. Tissue microarray for KMT2A alone
was purchased from Novus Biologicals (Littleton, CO, USA), with 59 melanoma tissues
from patients without anti-cancer treatments. OS was documented for all cases. IHC
staining for the microarray slides was performed as described in ref. 68.
Statistical analysis. Each experiment was done three times and the results
were presented as the mean± s.d. GraphPad Prism was used for statistical
analysis. Student’s t-test was used and *Po0.05, ***Po0.001, and ****Po0.0001
indicated significant difference.
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